Pharma updates from the Pharmalot campus via the Pharmalittle newsletter
Alex Hogan/STAT
By Ed Silverman
May 29, 2026
Pharmalot Columnist, Senior Writer
Ed Silverman
Replimune to ask FDA for re-review of melanoma drug, as agency stands by past rejections
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
The latest pharmaceutical news from the Pharmalot campus via the Pharmalittle newsletter
In this morning's Pharmalittle roundup, we're reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies,…
Replimune will resubmit advanced melanoma drug RP1 to the FDA after two rejections, following the ouster of Commissioner Marty…
A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance…
Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial
The FDA's new path, the status of animal testing, and other biotech news from The Readout
